Biotech · Public company · Burlington, MA, US
Minerva Neurosciences, Inc.
Ticker NERV · SEC CIK 0001598646
Track this companyFree. Adds Minerva Neurosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline10
- aripiprazolePhase 3 · Negative Symptoms of SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- olanzapinePhase 3 · Negative Symptoms of SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- risperidonePhase 3 · Negative Symptoms of SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- RoluperidonePhase 3 · Negative Symptoms of SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- Roluperidone 32 mgPhase 3 · Negative Symptoms of SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- Roluperidone 64 mgPhase 3 · Negative Symptoms of SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- MIN-117 2.5 mgPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- MIN-117 5.0 mgPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Olanzapine 10 MGPhase 1 · Negative Symptoms in SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- Roluperidone 64 mgPhase 1 · Negative Symptoms in SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsPHASE3 · RECRUITING · started Apr 23, 2026ClinicalTrials.gov NCT07565428 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaPHASE1 · COMPLETED · started Oct 13, 2023ClinicalTrials.gov NCT06107803 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive DisorderPHASE2 · COMPLETED · started Mar 30, 2018ClinicalTrials.gov NCT03446846 · fetched Nov 12, 2026
- Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of SchizophreniaPHASE3 · COMPLETED · started Dec 15, 2017ClinicalTrials.gov NCT03397134 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 27, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 2, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 11, 2026 · fetched Nov 12, 2026